文献速递前列腺癌

17基因GPS检测在MRI融合靶向联合系统穿刺活检中提供独立不良病理信息

A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
PubMed 文献 · J Urol · 2018-03-07

本研究纳入134例NCCN极低、低或中危前列腺癌患者,均接受多参数MRI融合靶向联合系统穿刺活检并在6个月内行根治性前列腺切除术。多变量分析显示,17基因前列腺评分检测(GPS)仍是不良病理的独立预测因子(每20单位OR 3.28,95%CI 1.74-6.62,p<0.001)。GPS结果在PI-RADS v2各评分间分布广泛且重叠。

要点

  • GPS检测在MRI融合活检背景下仍独立预测不良病理。
  • 每20单位GPS的OR为3.28(95%CI 1.74-6.62,p<0.001)。
  • GPS可独立或辅助MRI用于低中危前列腺癌风险分层。

核心结论

  • GPS检测结果是MRI融合靶向联合系统穿刺活检诊断的极低、低或中危前列腺癌患者不良病理的独立预测因子。

研究设计与样本

  • 回顾性研究纳入134例NCCN极低、低或中危前列腺癌患者,均接受多参数MRI融合靶向联合系统穿刺活检并在6个月内行根治性前列腺切除术。
  • GPS检测在活检组织中最高Gleason评分样本上进行。

主要发现

  • 单变量分析中UCLA评分、MRI、GPS结果和活检Gleason评分均是不良病理的显著预测因子。
  • 多变量调整后GPS值仍是不良病理的显著预测因子(每20单位OR 3.28,95%CI 1.74-6.62,p<0.001)。
  • GPS结果在PI-RADS v2各评分间分布广泛且重叠。

关键数值与推荐

  • 主要结局不良病理定义为根治性前列腺切除术后Gleason评分4+3或更高和/或pT3+。
  • GPS每20单位OR 3.28,95%CI 1.74-6.62,p<0.001。

临床怎么用

  • GPS可作为独立技术或MRI辅助技术,用于低中危前列腺癌的个体化风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiparametric magnetic resonance imaging and biopsy based molecular tests such as the 17-gene Oncotype DX® Genomic Prostate Score™ assay are increasingly performed to improve risk stratification in men with clinically localized prostate cancer. The prostate score assay was previously shown to be a significant independent predictor of adverse pathology findings at radical prostatectomy in men diagnosed by systematic biopsies only. Therefore, we investigated the ability of the prostate score assay to predict adverse pathology findings in the setting of magnetic resonance imaging guided prostate biopsy. MATERIALS AND METHODS: We identified men diagnosed with NCCN® (National Comprehensive Cancer Network®) very low, low or intermediate risk prostate cancer who underwent simultaneous multiparametric magnetic resonance imaging fusion targeted and systematic prostate biopsy with subsequent radical prostatectomy within 6 months. Prostate score assay testing was performed on biopsy tissue with the highest Gleason score. The primary outcome of the study was adverse pathology findings, defined as Gleason score 4 + 3 or greater disease and/or pT3+ at radical prostatectomy. Independent predictors of adverse pathology findings were determined in a multivariable model to adjust for clinical parameters. RESULTS: A total of 134 men were eligible for primary analysis. On univariable analysis the UCLA score, magnetic resonance imaging, prostate score assay results and biopsy Gleason score were significant predictors of adverse pathology findings. After multivariable adjustment prostate score assay values remained a significant predictor of adverse pathology results (prostate score assay per 20 U OR 3.28, 95% CI 1.74-6.62, p <0.001). A wide and overlapping distribution of prostate score assay results was seen across PI-RADS® (Prostate Imaging Reporting and Data System) version 2 scores. CONCLUSIONS: The prostate score assay result is an independent predictor of adverse pathology findings in patients who were diagnosed with very low, low or intermediate risk prostate cancer in the setting of multiparametric magnetic resonance imaging fusion prostate biopsy. This assay can be useful as an independent technology or an adjunct technology to multiparametric magnetic resonance imaging to individualize risk stratification of low and intermediate risk prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Salmasi A, Said J, Shindel AW, et al. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. J Urol. 2018. PMID: 29524506. doi:10.1016/j.juro.2018.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。